Diag-Nose.io Secures $2M Seed Funding to Revolutionize Respiratory Care with AI-Driven Precision Medicine

Innovative AI-Driven Respiratory Care Platform

Diag-Nose.io, a biotechnology startup founded in 2020, has successfully closed an oversubscribed $2 million seed funding round to advance its groundbreaking precision medicine system for respiratory diseases 1

1

2

2

3

3

. The company, a graduate of Stanford University's EENT Innovation Biodesign program, is pioneering a novel approach to respiratory healthcare by focusing on the "unified airway" concept, which emphasizes the biological relationship between the lungs and nasal passages 1

1

.

RhinoMAP™: Revolutionizing Respiratory Diagnostics

At the heart of Diag-Nose.io's innovation is the RhinoMAP™ platform, which combines machine learning (AI) with advanced proteomics to enable precision-matched treatments based on each patient's unique biological profile, or "endotype" 1

1

2

2

. The system utilizes the company's patented ABEL Microsampler™, a nasal liquid biopsy device, to collect nasal fluid samples for comprehensive biomarker analysis 1

1

2

2

.

Dr. Josie Xu, Co-Founder of Diag-Nose.io, explained, "By combining innovative nasal liquid biopsy techniques with proteomics and AI-driven analysis, we aim not only to enhance the adoption of current treatments but also to pave the way for future breakthroughs in areas such as sleep disorders and beyond" 1

1

.

Addressing Critical Gaps in Respiratory Care

Traditional diagnostic methods for chronic respiratory conditions such as asthma, chronic obstructive pulmonary disorder (COPD), and chronic sinusitis often rely on limited measurement tools and subjective assessments 1

1

2

2

. These flawed processes currently result in treatment failure for more than 30% of patients, costing hundreds of millions of dollars per year 1

1

.

Dr. Brian Wang, Co-founder and Co-Chief Scientific Officer of Diag-Nose.io, highlighted the need for objective tools in ENT treatments: "With RhinoMAP™, we aim to introduce biological benchmarks that give clinicians clear, data-driven insights into treatment effectiveness, enabling more confident and personalized care decisions" 3

3

.

Expansion and Future Plans

Following the successful funding round, Diag-Nose.io is expanding its operations. The company has announced new offices in Bethlehem, Pennsylvania, and Houston, Texas 2

2

3

3

. These strategic locations will allow Diag-Nose.io to foster partnerships with local health systems and advance clinical research efforts.

The company plans to launch a series of clinical studies across the United States in 2025 to further validate its technology 1

1

2

2

3

3

. Dr. Shannon Kearney, an allergist-investor at Specialty Physician Associates (SPA), expressed enthusiasm about the potential impact: "With the RhinoMAP™ and ABEL Microsampler™, we are planning to build a biobank that will advance our understanding of treatment efficacy across a variety of devices and drugs for respiratory disease" 2

2

.

Investor Support and Leadership

The oversubscribed $2 million round was led by Breakthrough Victoria, with additional investments from Radar Ventures, a syndicate of physicians from Specialty Physician Associates (SPA), and several biotech angel investors 1

1

2

2

3

3

. Carl Stubbings, one of the investors, will join Diag-Nose.io's board as Chairperson 1

1

.

Professor Robson Capasso from Stanford University School of Medicine praised the company's progress: "The team has not only demonstrated impressive scientific progress despite the pandemic, but they have also grown increasingly ambitious. It makes them well-positioned to tackle one of the burning problems in respiratory care right now; matching patients to the right biologic therapy" 1

1

.